|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2215 CONSTITUTION AVENUE, NW |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20037-2985 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 3071-12
|
||||||||
|
6. House ID# 316200000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Allison C. Wiley, Political Action Coordinator |
Date | 07/20/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR616/S511 - Access to Durable Medical Equipment Act
HR203 - Medicare Fraud Prevention Act of 2009
HR27 - Medicare Fraud Prevention and Enforcement Act of 2009
HR574 - Medicare Home Infusion Therapy Coverage Act of 2009
S266 - Medicare Prescription Drug Gap Reduction Act of 2009
HR2560/S1131 - Independence At Home Act
HR1970/S956 - Preserve Patient Access to the Reputable DMEPOS Providers Act of 2009
HR3700/S1951 - Fair Medicaid Drug Payment Act (From 110th Congress)/Concept to Include Medicaid Average Manufacturer Price Reimbursement Formula in Health Care Reform
(Public Law 110-275) Medicare Improvements for Patients and Providers Act of 2008 Sections on Medicare DMEPOS
(Docket Number: CMS1561IFC) Medicare Program; Changes to the Competitive Acquisition of Certain Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) by Certain Provisions of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA)
(Docket Number: CMS-1540-F) Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2007; Certain Provisions Concerning Competitive Acquisition for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS); Accreditation of DMEPOS Suppliers
(Docket Number: CMS-6006-F) Medicare Program: Surety Bond Requirement for Suppliers of Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS)
Solicitation for Comments on the Draft CMS Model Transition Letter for Calendar Year 2010
Draft 2010 Medicare Part D Call Letter
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristina |
Lunner |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
HR1204 - The Community Pharmacy Fairness Act of 2009
S80 - Pharmaceutical Market Access Act of 2009
S525/HR1298 - Pharmaceutical Market Access and Drug Safety Act of 2009
HR163 - Prescription Drug Affordability Act
HR2400 - Strategies to Address Antimicrobial Resistance Act
HR1706 - Protecting Consumer Access to Generic Drugs Act of 2009
(Docket No. DEA322I) Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008
(Docket No. FDA2009N0143) Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting
(Docket Number: FDA-2008-P-0380) Citizen Petition: Requesting a FDA Action on a "One Document Solution" for all Pharmacy-Based Communications
(Docket Number FDA2008N0038) Risk Communication Advisory Committee; Notice of Meeting (focused on the types of communications that patients receive at the pharmacy includes: medication guides; patients package inserts; and consumer medication information)
(Docket Number: FDA2009D0001) Draft Guidance for Industry on Standards for Securing the Drug Supply ChainStandardized Numerical Identification for Prescription Drug Packages; Availability
(Docket Number: FDA-2008-S-0627) Expert and Consumer Evaluation of Consumer Medication Information -- 2008
(Docket No. FDA1977N0013) (formerly Docket No. 1977N0094L) Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Final Monograph
(Docket No. FDA2009D0181) Draft Guidance for Industry on Label Comprehension Studies for Nonprescription Drug Products; Availability
(Docket No. FDA2009N0138) Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee; Notice of Meeting
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristina |
Lunner |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR756/S660 - National Pain Care Policy Act of 2009
HR179 - Community AIDS and Hepatitis Prevention Act
S1213 - A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research.
HR2891 - Access to Frontline Health Care Act of 2009
HR1259 - The Dextromethorphan Distribution Act of 2009
HR1256 - Family Smoking Prevention and Tobacco Control Act on S.A. 1229 - Pharmaceutical Market Access and Drug Safety Act of 2009
(Docket Number: IRS-2006-0502) Employer Comparable Contributions to Health Savings Accounts Under Section 4980G
(74 FR 28937) Draft Recommendations for the Term Meaningful Use" of Electronic Health RecordsConcept
(Docket Number 105A) Updating the List of Hazardous Drugs for the NIOSH Alert: Additions and Deletions to the NIOSH Hazardous Drug List
Concept (No Bill Language) Utilizing E-Prescribing Technologies to Integrate Pharmacogenomics into Prescribing and Dispensing Practices
Concept (No Bill Language) CBO Scoring of Prevention and Chronic Disease Management in Health Care Reform
Draft Bill Access to Birth Control Act
Draft Bill Affordable Health Choices Act (Sections on ensuring quality of care; affordable choices of health benefit plans; seeking the best medical advice; spending for Federally Qualified Health Centers (FQHCs); national strategy; presentation of drug information; center for health outcomes research and evaluation; administrative simplification; right choices program; grants to establish community health teams to support a medical home model; grants to implement medication management services in treatment of chronic disease; national health care workforce commission; funding for National Health Service Corps; geriatric education and training, career awards, comprehensive geriatric education; nurse education, practice, and retention grants; and increase prevention and wellness provisions)
Draft Bill - America's Affordable Health Choices Act of 2009 HR3200 [(no bill name or number during reporting period) Sections on ensuring adequacy of provider networks; essential benefits package defined; Health Benefits Advisory Committee; outreach and enrollment of Exchange-eligible individuals and employers in Exchange-participating health benefits plan; payment rates for items and services; reducing potentially preventable hospital readmissions; post acute care services payment reform plan; requiring drug manufacturers to provide drug rebates for certain, full premium subsidy eligible individuals; phasedin elimination of coverage gap; repeal of provision relating to submission of claims by pharmacies located in or contracting with long-term care facilities; including costs incurred by AIDS drug assistance programs and Indian Health Service in providing prescription drugs toward the annual out of pocket threshold under part D; permitting mid-year changes in enrollment; telehealth expansion and enhancements; intelligent assignment in enrollment; ensuring effective communication in Medicare; Accountable Care Organization pilot program; medical home pilot program; coverage and waiver of cost-sharing for preventive services; comparative effectiveness research; reports on financial relationships between manufacturers and distributors of covered drugs, devices, biologicals, or medical supplies under Medicare, Medicaid, or CHIP and physicians and other health care entities and between physicians and other health care entities; distribution of unused residency positions; require providers and suppliers to adopt programs to reduce waste, fraud, and abuse, payments to pharmacists; Task Force on Clinical Preventive Services; fully integrated dual eligible special needs plans (FIDESNP); public health and workforce development; prevention and wellness; and sections 212 (grants to establish community health teams to support a medical home model) and 213 (grants to implement medication management services in treatment of chronic disease) from the Senate HELP Committee's Draft Affordable Health Choices Act]
Commented on Senate Finance Committee Report on Expanding Health Care Coverage and Senate Finance Committee Report on Transforming the Health Care Delivery System
Concept Role of Pharmacist-Provided Patient Care Services in any Integrated Care Model and Medication Therapy Management Services in Health Care Reform
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Internal Revenue Service (IRS), Centers For Disease Control & Prevention (CDC),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristina |
Lunner |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
(Public Law 111-5) American Recovery and Reinvestment Act of 2009 Sections on Health Information Technology
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kristina |
Lunner |
|
|
|
Marcie |
Bough |
|
Former Legislative Assistant |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | 2215 Constitution Avenue, NW |
||||||
City | Washington |
State | DC |
Zip Code | 20037-2985 |
Country | USA |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |